Form 4: Bicycle Therapeutics CEO Reports Equity Transactions

Bicycle Therapeutics CEO Kevin Lee reported the acquisition of restricted stock units and stock options, alongside mandated 'sell to cover' transactions for tax obligations.

Summary

• Kevin Lee, Chief Executive Officer and Director of Bicycle Therapeutics PLC, reported transactions involving the company's ordinary shares and employee stock options.
• On January 2, 2026, Mr. Lee was awarded 165,000 Restricted Share Units (RSUs), with each RSU representing a contingent right to receive one ordinary share. These RSUs will vest one-fourth on January 2, 2027, and the remainder in 12 equal quarterly installments thereafter.
• Also on January 2, 2026, Mr. Lee was granted 330,000 Employee Stock Options with an exercise price of $7.08. These options will vest one-fourth on January 2, 2027, and the remaining shares in 36 equal monthly installments thereafter, expiring on January 2, 2036.
• To cover statutory tax withholding obligations related to the vesting and settlement of RSUs, Mr. Lee sold 10,325 ordinary shares on January 2, 2026, at a weighted average price of $6.80 per share (ranging from $6.62 to $7.11).
• Additionally, 10,989 ordinary shares were sold on January 5, 2026, for the same tax withholding purpose, at a weighted average price of $6.46 per share (ranging from $6.30 to $6.70).
• These sales were mandated 'sell to cover' transactions as per Mr. Lee's award agreement and do not represent discretionary sales.
• Following these transactions, Mr. Lee beneficially owns 618,996 ordinary shares and 330,000 employee stock options.

Sentiment

Score: 7

Explanation: The grant of significant equity awards to the CEO is a positive indicator of long-term commitment and alignment with shareholder interests. The subsequent 'sell to cover' transactions are routine and non-discretionary for tax purposes, thus having a neutral impact on sentiment.

Positives

• The grant of 165,000 Restricted Share Units and 330,000 Employee Stock Options to the CEO indicates a strong commitment to long-term incentive alignment with shareholder interests.
• The vesting schedules for both RSUs and stock options extend several years into the future, reinforcing management's long-term focus on company performance.

Negatives

• The sale of 21,314 ordinary shares, even if for tax purposes, reduces the CEO's direct beneficial ownership of the company's stock.

Future Outlook

The equity awards granted to the CEO, with vesting schedules extending into 2027 and beyond, indicate a long-term incentive structure designed to align management's interests with the company's sustained performance and shareholder value creation.

Management Comments

• The sales of shares were 'required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs' and 'does not represent a discretionary sale by the Reporting Person'.

Industry Context

This Form 4 filing details routine insider transactions related to equity compensation and tax management, which are standard practices across all industries, including the biotechnology sector. It does not provide specific insights into broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: The significant equity grants to the CEO reinforce alignment between management and shareholder interests for long-term value creation. The 'sell to cover' transactions are minor and routine, unlikely to have a material impact.
• Employees: The filing reflects standard equity compensation practices for executive leadership, which can be a positive signal for broader employee incentive programs.

Next Steps

• Vesting of 165,000 RSUs: One-fourth on January 2, 2027, with the remainder vesting in 12 equal quarterly installments thereafter.
• Vesting of 330,000 Employee Stock Options: One-fourth on January 2, 2027, with the remaining shares vesting in 36 equal monthly installments thereafter.

Key Dates

Recommendation

This Form 4 filing details routine equity compensation grants and subsequent non-discretionary 'sell to cover' transactions by the CEO. It does not provide new information about the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. The grants align management incentives with long-term shareholder value, which is a neutral to slightly positive factor, but not enough to change a fundamental view. Therefore, a 'hold' recommendation is appropriate based solely on this filing.

Keywords

Bicycle Therapeutics, BCYC, Kevin Lee, Insider Trading, Restricted Stock Units, Stock Options, Equity Compensation, Sell to Cover, Biotechnology, Pharmaceuticals